CLINICAL RESEARCH STUDY
|
|
- Katherine Wilson
- 6 years ago
- Views:
Transcription
1 CLINICAL RESEARCH STUDY Determining Triglyceride Reductions Needed for Clinical Impact in Severe Hypertriglyceridemia Jennifer B. Christian, PharmD, MPH, PhD, a Bhakti Arondekar, BPharm, MBA, PhD, b Erin K. Buysman, MS, c Terry A. Jacobson, MD, d Rose G. Snipes, MD, e Ralph I. Horwitz, MD f a Clinical Effectiveness and Safety, GlaxoSmithKline, Durham, NC; b US Health Outcomes, GlaxoSmithKline, Philadelphia, Pa; c Health Economics and Outcomes, OptumInsight, Eden Prairie, Minn; d Department of Medicine, Emory University, Atlanta, Ga; e Medicines Discovery & Development, GlaxoSmithKline, Durham, NC; f Clinical Effectiveness and Safety, GlaxoSmithKline, Philadelphia, Pa. ABSTRACT BACKGROUND: Patients with severe hypertriglyceridemia have an increased risk of cardiovascular disease and pancreatitis. Target triglyceride levels associated with clinical benefit for patients with severe hypertriglyceridemia are not currently known. This study evaluates the association between lower follow-up triglyceride levels and incidence of clinical events for patients with severe hypertriglyceridemia. METHODS: By using claims data from 2 large US healthcare databases, we conducted a retrospective cohort study and identified 41,210 adults with severe hypertriglyceridemia (triglycerides 500 mg/dl) between June 2001 and September The date of the first severe hypertriglyceridemia laboratory result was the index date. Patients were categorized into 1 of 5 triglyceride ranges (<200 mg/dl, mg/dl, mg/dl, mg/dl, and 500 mg/dl) based on a follow-up triglyceride level assessed 6 to 24 weeks after initial triglyceride levels were measured. Adjusted Cox regression models were developed to evaluate the impact of follow-up triglyceride levels on rates of pancreatitis episodes and cardiovascular events. RESULTS: The mean age of patients was 50 years, 72% were male, and the mean follow-up was 825 days. Patients with severe hypertriglyceridemia with follow-up triglyceride levels <200 mg/dl experienced a lower rate of pancreatitis episodes (adjusted incidence rate ratio, 0.45; 95% confidence interval, ) and cardiovascular events (adjusted incidence rate ratio, 0.71; 95% confidence interval, ) with some clinical benefit in adults with severe hypertriglyceridemia with follow-up triglyceride levels 200 to 299 mg/dl and 300 to 399 mg/dl (P <.001 for trend). CONCLUSIONS: We observed the greatest impact on clinical events among patients with severe hypertriglyceridemia with the lowest follow-up triglyceride levels. Ó 2014 Elsevier Inc. All rights reserved. The American Journal of Medicine (2014) 127, KEYWORDS: Cardiovascular; Epidemiology; Pancreatitis; Severe hypertriglyceridemia There are approximately 3 to 4 million adults in the United States with severe hypertriglyceridemia, defined as having triglyceride levels 500 mg/dl. 1 Triglyceride levels 150 mg/dl are associated with an increased risk of Funding: This study was supported by GlaxoSmithKline. Conflict of Interest: JBC, BA, RS, and RH are employees of and own stock in GlaxoSmithKline. TJ is a consultant for Abbott, Amarin, GlaxoSmithKline, and Merck. EKB has no conflict of interest to report. Authorship: All authors had access to the data and played a role in writing this manuscript. Requests for reprints should be addressed to Jennifer B. Christian, PharmD, MPH, PhD, GlaxoSmithKline, 5 Moore Drive, B.3116, Durham, NC address: Jennifer.B.Christian@GSK.com cardiovascular disease in men and women. 2 Severe hypertriglyceridemia is associated with an even greater risk of acute pancreatitis, 3 premature coronary heart disease, 4,5 and mortality due to cardiovascular disease. 6 Some of the risk factors associated with severe hypertriglyceridemia include genetic disorders, lifestyle factors (eg, excess alcohol intake, cigarette smoking, physical inactivity, and high carbohydrate diets), certain drugs (eg, hormone therapy), and other diseases (eg, type 2 diabetes, chronic renal failure, and metabolic syndrome). 7 The current guidelines from the National Cholesterol Education Program Adult Treatment Panel III 7 recommend reducing triglycerides to less than 500 mg/dl to prevent acute pancreatitis before addressing issues related to /$ -see front matter Ó 2014 Elsevier Inc. All rights reserved.
2 Christian et al Triglyceride Levels and Clinical Impact 37 nonehigh-density lipoprotein cholesterol and low-density lipoprotein cholesterol for patients with severe hypertriglyceridemia. Indeed, one study 8 found that 20% of patients with severe hypertriglyceridemia experience at least 1 episode of acute pancreatitis, the majority of which were considered severe. Therefore, the primary clinical recommendations for patients with severe hypertriglyceridemia are to decrease triglycerides to first reduce the risk of acute pancreatitis, with a secondary focus on decreasing cardiovascular risk. Guideline recommendations for reducing triglycerides include the use of triglyceride-lowering treatments (eg, fibrates, niacin, and omega-3 fatty acids), in addition to lifestyle modification (eg, weight control and increased physical activity). Although lowering triglyceride levels is recommended to reduce the risk of coronary heart disease and cardiovascular events, 9 there is little evidence to demonstrate the impact of triglyceride reductions on the risk of clinical events in patients with severe CLINICAL SIGNIFICANCE hypertriglyceridemia In addition, among patients with severe hypertriglyceridemia, the level of triglyceride reduction that is associated with a reduced risk is not currently known. The primary objective of this study was to examine the association between the follow-up triglyceride levels and the incidence of pancreatitis episodes and cardiovascular events among patients with severe hypertriglyceridemia. Although target triglyceride levels associated with clinical benefit for patients with severe hypertriglyceridemia (500 mg/dl) currently are not known, our study showed that patients with severe hypertriglyceridemia who decreased their triglyceride levels to <200 mg/dl experienced the greatest benefit. Patients with triglycerides of <200 mg/ dl at follow-up had lower rates of pancreatitis and cardiovascular events, such as acute myocardial infarction, ischemic stroke, heart failure, revascularization procedures, and acute coronary syndrome. The results reflect real-world, objective clinical data from a large geographically diverse patient population over 2 years. All study data were accessed using techniques compliant with the Health Insurance Portability and Accountability Act of 1996, 13 and no identifiable protected health information was extracted during the course of the study. Because this study involved analysis of preexisting, de-identified data, institutional review board approval was not required. Study Patient Identification We identified 104,817 adult patients who had at least 1 triglyceride laboratory result 500 mg/dl during the study period between June 1, 2001, and September 30, 2010; had continuous enrollment with medical and pharmacy claims for 6 months before the index date and at least 90 days after the index date; and had no medical claims indicating pregnancy. The index date was the date of the first severe hypertriglyceridemia laboratory result during the study period. We then limited our sample to the 41,210 patients who had at least 1 followup triglyceride laboratory result during a period of 6 to 24 weeks after the index date. The date of the earliest triglyceride laboratory result in this period was set as the follow-up laboratory date. Patients were then categorized into 1 of 5 follow-up triglyceride level ranges on the basis of their follow-up triglyceride laboratory result (<200 mg/dl, mg/dl, mg/dl, mg/dl, and 500 mg/dl). MATERIALS AND METHODS Data Sources This was a retrospective cohort study using medical, pharmacy, laboratory, and enrollment claims information from 2 large, US health care claims databases (Optum s Research Database; IMPACT National Benchmarking Database [formerly known as IHCIS]). Individuals covered by these health plans have medical and pharmacy benefits through commercial or Medicare Advantage insurance and are geographically diverse across the United States. Medical (professional, facility) claims included International Classification of Diseases, 9th Revision, Clinical Modification (ICD- 9-CM) diagnosis codes, ICD-9 procedure codes, Current Procedural Terminology, Version 4 procedure codes, Healthcare Common Procedure Coding System procedure codes, and site of service codes. Outpatient pharmacy claims provided National Drug Codes for dispensed medications, quantity dispensed, drug strength, and number of days of supply. Study Measures Patient Demographics and Baseline Clinical Characteristics. The patient characteristics that were examined included age, gender, insurance type, geographic location, and length of the follow-up period (days). The baseline clinical characteristics that were collected during the 6 months preceding the index date included the Quan- Charlson comorbidity score, 14 history of cardiovascular disease, hypertension, dyslipidemia, diabetes mellitus, pancreatitis, chronic kidney disease, end-stage renal disease, and medication use (statins, triglyceride-lowering agents, hormone replacement therapy, steroids, and beta-blockers). The use of statins and triglyceride-lowering medications also was evaluated during the period between the index triglyceride result and the follow-up triglyceride result. Also examined were baseline triglycerides, total cholesterol, high-density lipoprotein, and nonehigh-density lipoprotein values.
3 38 The American Journal of Medicine, Vol 127, No 1, January 2014 Outcomes. The follow-up period began with the day after the follow-up laboratory date and ended with patient disenrollment, pregnancy, or study end (December 31, 2010), whichever occurred first. The clinical outcomes examined during the follow-up period included pancreatitis episodes and composite and individual cardiovascular events. Episodes of pancreatitis were determined using the primary diagnosis in a patient s medical claim of ICD-9-CM or Claims for cardiovascular events were identified with a primary diagnosis or procedure code indicating acute myocardial infarction, stroke (ischemic or hemorrhagic), heart failure, coronary revascularization procedures (percutaneous coronary intervention, coronary artery bypass graft, percutaneous transluminal angioplasty), acute coronary syndrome, or sudden death. If patients had multiple cardiovascular events, the time to the first event was captured for each type of event. An overall cardiovascular event measure was captured on the basis of the presence of any of individual events described earlier. The codes used to identify all of the clinical outcomes in this study are included in Appendix Table 1 (online). Analysis. Patient demographics and baseline clinical characteristics were analyzed descriptively. For each outcome of interest, crude incidence rate ratios (IRRs) were calculated and multivariate Cox proportional hazards models were developed to adjust for key confounders. Hazard ratios were interpreted as adjusted IRRs (IRR adj ). Covariates for each model were selected on the basis of clinical relevance and model fit, and are listed in Appendix Table 2 (online). Patients whose triglyceride levels remained elevated 500 mg/dl at the follow-up laboratory measurement were considered the reference group for all IRR adj. In addition, several post hoc analyses were conducted to determine the number of patients who developed pancreatitis in the follow-up period with baseline and follow-up triglyceride levels 1000 mg/dl. The study population was stratified by baseline triglyceride levels of 500 to 999 mg/dl and 1000 mg/dl to compare crude incidence rates and IRRs of pancreatitis episodes by follow-up triglyceride level, including an additional follow-up group of triglyceride level 1000 mg/dl. A second post hoc analysis was conducted to assess the risk of pancreatitis in patients with no evidence of pancreatitis in the baseline period. RESULTS Figure 1 displays the criteria used in the patient selection process. After applying all of the selection criteria, 41,210 patients were included in the study. Patients had an average of 94 days between the date of their index severe hypertriglyceridemia value and their follow-up triglyceride result. Approximately 79% of the patients with severe hypertriglyceridemia (n ¼ 32,717) experienced a reduction in triglyceride levels to <500 mg/dl between the index date and the follow-up laboratory date. Approximately 25% of patients had a follow-up triglyceride level <200 mg/dl. Table 1 displays the baseline patient demographics and clinical characteristics for the entire sample and for each of the 5 triglyceride groups based on their follow-up triglyceride levels. Patients were followed for an average of 825 days after the follow-up laboratory date. Overall, 72% were male with a mean age of 50 years, 91% of all patients were commercially insured, and 53% of all patients were living in the South. The overall mean Quan-Charlson comorbidity index score was 0.89, and the overall percentage of patients with each baseline comorbidity of interest included dyslipidemia (41%), hypertension (32%), diabetes (21%), cardiovascular disease history (11%), chronic kidney disease/end-stage renal disease (3%), and pancreatitis (<1%). A significantly greater percentage of patients with a follow-up triglyceride level 500 mg/dl had a history of diabetes and pancreatitis when compared with each of the other 4 triglyceride groups. Medication use during the baseline period is shown in Table 1. Medication use in the total sample included statins (31%), triglyceride-lowering medications (14%), betablockers (21%), steroids (12%), and hormone replacement therapy (4%). Patients with a follow-up triglyceride level 500 mg/dl were more often prescribed at least 1 triglyceride-lowering medication in the baseline period when compared with each of the other 4 triglyceride groups (10%, <200 mg/dl; 13%, mg/dl; 15%, mg/dl; 16%, mg/dl; 20%, 500 mg/dl; P <.001, all triglyceride groups). In the period between the index triglyceride result and the follow-up laboratory date ( index period), the use of triglyceride-lowering therapy was significantly higher among patients with follow-up triglyceride levels between 200 and 299 mg/dl (36%; P <.001) and <200 mg/dl (43%; P <.001) compared with patients with follow-up triglyceride levels 500 mg/dl (30%). Figure 2 shows the mean and interquartile range for baseline and follow-up laboratory results for each of the 5 follow-up triglyceride level groups. Because low-density lipoprotein cholesterol cannot be measured reliably in patients with severe hypertriglyceridemia, nonehighdensity lipoprotein cholesterol was calculated as total cholesterol minus high-density lipoprotein cholesterol. The mean baseline laboratory values across all patients were 761 mg/dl for triglycerides, 250 mg/dl for total cholesterol, 213 mg/dl for nonehigh-density lipoprotein, and 37 mg/dl for high-density lipoprotein. The mean follow-up laboratory values across all patients were 385 mg/dl for triglycerides, 200 mg/dl for total cholesterol, 160 mg/dl for none high-density lipoprotein, and 40 mg/dl for high-density lipoprotein. Figure 3 displays the crude incidence rates, per 100 person-years, for each clinical outcome of interest in the follow-up period. The incidence rates for pancreatitis ranged from 0.40 per 100 person-years for patients with follow-up triglyceride levels <200 mg/dl to 1.09 per 100 person-years for patients with follow-up triglyceride levels 500 mg/dl.
4 Christian et al Triglyceride Levels and Clinical Impact 39 Figure 1 Patient selection. Likewise, the incidence rates for overall cardiovascular events ranged from 3.62 per 100 person-years among patients with follow-up triglyceride levels <200 mg/dl to 6.06 per 100 person-years among patients with follow-up triglyceride levels 500 mg/dl. A trend test indicated that there was a significant linear trend associated with patients with lower follow-up triglyceride levels for the crude rates associated with each of the clinical events in the follow-up period (P <.001) for all outcomes except for hemorrhagic stroke and sudden death (data not shown). The incidence rates for each of the clinical events in the follow-up period increased with increasing triglyceride levels tested at the follow-up laboratory date. Figure 4 displays the IRR adj for each of the clinical outcomes in the follow-up period. Cox proportional hazards models were used to adjust the IRRs for clinically important covariates. Patients with severe hypertriglyceridemia with follow-up triglyceride levels <200 mg/dl were significantly less likely to experience all of the clinical events in the follow-up period when compared with the patients with severe hypertriglyceridemia whose follow-up triglyceride levels were 500 mg/dl: pancreatitis IRR adj : 0.45 [95% confidence interval {CI}, ]; cardiovascular event IRR adj : 0.71 [95% CI, ]; acute myocardial infarction IRR adj : 0.64 [95% CI, ]; ischemic stroke IRR adj : 0.64 [95% CI, ]; heart failure IRR adj : 0.66 [95% CI, ]; revascularization IRR adj : 0.62 [95% CI, ]; and acute coronary syndrome IRR adj : 0.72 [95% CI, ]. Hemorrhagic stroke and sudden death were excluded from the multivariate analysis given the limited number of total events in these categories. Also when adjusted for key covariates, patients with severe hypertriglyceridemia with follow-up triglyceride
5 Table 1 Baseline Demographics and Clinical Characteristics Follow-Up Triglyceride Level <200 mg/dl (N ¼ 10,074) mg/dl (N ¼ 9950) (N ¼ 7709) mg/dl (N ¼ 4984) 500 mg/dl (N ¼ 8493) Total (N ¼ 41,210) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Age, y 50.4 (11.2) 49.9 (11.1) 50.7 (11.3) 50.8 (11.3) 51.2 (11.4) 50.1 (11.1) Follow-up (d) (722.8) (703.6) (722.3) (712.8) (741.7) (742.4) Quan-Charlson 0.9 (1.4) 0.7 (1.2) 0.8 (1.4) 0.9 (1.5) 1.0 (1.6) 1.1 (1.6) Age Groups, y n (%) n (%) n (%) n (%) n (%) n (%) ,500 (30.3) 3200 (31.8) 2981 (30.0) 2287 (29.7) 1383 (27.7) 2649 (31.2) ,614 (59.7) 5991 (59.5) 5953 (59.8) 4596 (59.6) 3038 (61.0) 5036 (59.3) (9.9) 883 (8.8) 1016 (10.2) 826 (10.7) 563 (11.3) 808 (9.5) Gender n (%) n (%) n (%) n (%) n (%) n (%) Male 29,596 (71.8) 7547 (74.9) 7075 (71.1) 5304 (68.8) 3479 (69.8) 6191 (72.9) Female 11,614 (28.2) 2527 (25.1) 2875 (28.9) 2405 (31.2) 1505 (30.2) 2302 (27.1) Baseline comorbidities n (%) n (%) n (%) n (%) n (%) n (%) Cardiovascular disease history 4356 (10.6) 901 (8.9) 1021 (10.3) 896 (11.6) 576 (11.6) 962 (11.3) Hypertension 13,127 (31.8) 2982 (29.6) 3161 (31.8) 2533 (32.9) 1667 (33.4) 2784 (32.8) Dyslipidemia 16,946 (41.1) 3999 (39.7) 4129 (41.5) 3223 (41.8) 2072 (41.6) 3523 (41.5) Diabetes (type 1 or 2) 8790 (21.3) 1574 (15.6) 1962 (19.7) 1729 (22.4) 1215 (24.4) 2310 (27.2) Pancreatitis 214 (0.5) 44 (0.4) 29 (0.3) 31 (0.4) 26 (0.5) 84 (1.0) Chronic kidney disease/end-stage renal disease 1177 (2.9) 214 (2.1) 270 (2.7) 236 (3.1) 155 (3.1) 302 (3.6) Baseline medication use n (%) n (%) n (%) n (%) n (%) n (%) Statins 12,742 (30.9) 2915 (28.9) 3040 (30.5) 2453 (31.8) 1626 (32.6) 2708 (31.9) Triglyceride-lowering medication 5952 (14.4) 1054 (10.5) 1276 (12.8) 1144 (14.8) 773 (15.5) 1705 (20.1) Hormone replacement therapy 1692 (4.1) 307 (3.0) 419 (4.2) 336 (4.4) 235 (4.7) 395 (4.6) Steroids 5134 (12.5) 1139 (11.3) 1266 (12.7) 989 (12.8) 640 (12.8) 1100 (12.9) Beta-blockers 8555 (20.8) 1681 (16.7) 1965 (19.7) 1724 (22.4) 1224 (24.6) 1961 (23.1) Index medication use n (%) n (%) n (%) n (%) n (%) n (%) Statins 15,509 (37.6) 3774 (37.5) 3779 (38.0) 2955 (38.3) 1909 (38.3) 3092 (36.4) Triglyceride-lowering medication 14,356 (34.8) 4314 (42.8) 3606 (36.2) 2389 (31.0) 1479 (29.7) 2568 (30.2) SD ¼ standard deviation. 40 The American Journal of Medicine, Vol 127, No 1, January 2014
6 Christian et al Triglyceride Levels and Clinical Impact 41 Figure 2 Laboratory results stratified by follow-up triglyceride level (mg/dl). levels between 200 and 299 mg/dl experienced a lower rate of pancreatitis episodes (IRR adj : 0.46 [95% CI, ]), overall cardiovascular events (IRR adj : 0.81 [95% CI, ]), acute myocardial infarction (IRR adj : 0.77 [95% CI, ]), heart failure (IRR adj : 0.77 [95% CI, ]), revascularization (IRR adj : 0.79 [95% CI, Figure 3 Crude incidence rates (per 100 person-years) for clinical events in the follow-up period stratified by follow-up triglyceride level (mg/dl).
7 42 The American Journal of Medicine, Vol 127, No 1, January 2014 Figure 4 Adjusted IRRs* for clinical events in the follow-up period stratified by follow-up triglyceride level (mg/dl). Reference group is follow-up triglyceride levels 500 mg/dl ]), and acute coronary syndrome (IRR adj : 0.76 [95% CI, ]) compared with patients with severe hypertriglyceridemia with follow-up laboratory results >500 mg/dl. In addition, patients with severe hypertriglyceridemia with a follow-up triglyceride level between 300 and 399 mg/dl had a significantly lower adjusted incidence for pancreatitis (IRR adj : 0.64 [95% CI, ]); overall cardiovascular events (IRR adj : 0.88 [CI, ]); and heart failure (IRR adj : 0.77 [CI, ]) compared with patients with a follow-up triglyceride level that remained elevated at 500 mg/dl. In contrast, the event rates for patients with follow-up triglyceride levels between 400 and 499 mg/dl were not significantly different from the patients with follow-up triglyceride levels 500 mg/dl, except for ischemic stroke (IRR adj : 0.67 [95% CI, ]) in the follow-up period. The post hoc analysis of the risk of pancreatitis in patients without evidence of prior pancreatitis at baseline showed similar results of the analysis in the overall sample. Adjusted incidence rates among patients without evidence of prior pancreatitis at baseline indicated lower risk of pancreatitis in patients who decreased their triglycerides to 300 to 399 mg/dl (IRR adj : 0.60 [95% CI, ]), 200 to 299 mg/dl (IRR adj : 0.45 [95% CI, ]), and <200 mg/dl (IRR adj : 0.43 [95% CI, ]) compared with patients with triglyceride levels 500 mg/dl. Other post hoc results indicated that although patients with baseline triglyceride levels 1000 mg/dl experienced higher
8 Christian et al Triglyceride Levels and Clinical Impact 43 crude incidence rates of pancreatitis, they had similar IRRs as patients with baseline triglyceride levels 500 to 999 mg/dl (data not shown) when compared by follow-up triglyceride levels. DISCUSSION In this large retrospective claims study, we found that lower follow-up triglyceride levels were associated with a lower incidence of important clinical events for patients with severe hypertriglyceridemia. Some clinical benefit was found for patients with severe hypertriglyceridemia whose follow-up triglyceride levels were <400 mg/dl. However, the greatest clinical benefit was observed among those patients whose follow-up triglyceride level was <200 mg/dl, which included a significant reduction in the rates of pancreatitis and overall and individual cardiovascular events. Although severe hypertriglyceridemia treatment guidelines focus on lowering triglyceride levels to reduce the risk of acute pancreatitis and cardiovascular disease, 7 clear evidence has been lacking for the extent to which reduced triglyceride levels could decrease the rate of cardiovascular outcomes. 9 Indeed, the independent relationship of elevated triglycerides and increased risk of future cardiovascular events has long been controversial. Some studies have found that the beneficial effects of reducing triglyceride levels on cardiovascular disease were attenuated after adjusting for established risk factors, such as blood pressure, total cholesterol, low-density lipoprotein cholesterol, and low levels of high-density lipoprotein cholesterol Furthermore, although the benefit of lowering triglyceride levels has been recognized, target triglyceride levels that are associated with a reduced risk of cardiovascular disease have not been identified, particularly in patients with severe hypertriglyceridemia. 9 Study Limitations Our previous study used a threshold follow-up triglyceride laboratory value of <500 mg/dl based on current guidelines and examined the association between follow-up triglyceride levels <500 mg/dl and clinical outcomes and their associated costs. 10 The current study focused on the relationship between follow-up triglyceride level ranges and their associated rates of clinical outcomes. Our results suggest that <500 mg/dl may represent a critical threshold for lower cardiovascular events in patients with severe hypertriglyceridemia, but follow-up triglyceride levels <200 mg/dl could result in even greater clinical benefit for the patient. Although it is beyond the scope of our database analysis to measure and examine the impact of different interventions on lower follow-up triglyceride levels, we did find a greater proportion of patients with follow-up laboratory results <300 mg/dl initiating triglyceridelowering medications between the baseline and the followup laboratory period compared with patients with severe hypertriglyceridemia with follow-up triglyceride levels 500 mg/dl (<200 mg/dl: 43%; mg/dl: 36%; 500 mg/dl 30%, P <.001). However, our claims database does not capture many variables that are often associated with reducing (or increasing) triglyceride levels, such as lifestyle modifications (eg, diet and exercise), restricted alcohol and fat intake, smoking cessation, improved management of comorbidities, and normal physiologic variations in triglyceride levels. Also, ethnicity, smoking, and body mass index were not available in our claims database. However, the intent of this study was to evaluate the association between follow-up triglyceride levels and incidence of clinical events rather than specific interventions used to reduce triglycerides. Another limitation is that fasting status is not available in claims data, so the triglyceride laboratory results may have included elevated triglyceride levels that were not an accurate reflection of the patient s true triglyceride level, with the subsequent assignment of some patients to the incorrect follow-up triglyceride level group. However, this bias would result in more patients being classified as having falsely higher follow-up triglyceride levels, which would likely attenuate the results. In addition, recent studies have suggested that elevated nonfasting triglyceride levels may be a better predictor of cardiovascular events than fasting triglyceride levels. 19,20 Finally, some patients with severe hypertriglyceridemia may have been excluded from this study because of missing triglyceride laboratory results, and some of the laboratory results may have been missing for those patients who did have laboratory data. However, missing laboratory results are a function of the processing center that supplies the results; therefore, it is expected that patients with missing laboratory results should not be systematically different from the patients without missing laboratory results. Despite the potential limitations, this study provides a real-world view of the relationship between triglyceride levels and the incidence of important clinical events. Our study had a large sample of patients with continuous followup for an average of 2.2 years, and data are based on claims rather than self-report. The databases used in this study contain claims from a wide geographic distribution of patients across the United States; therefore, our results are applicable to members of managed care populations at a national level. CONCLUSIONS In this large retrospective claims study, we observed that lower levels of triglycerides at follow-up were associated with larger reductions in incidence of important clinical events for patients with severe hypertriglyceridemia. Some clinical benefit was observed for patients with severe hypertriglyceridemia with follow-up triglyceride levels <400 mg/dl. However, the greatest clinical benefit was found for patients with severe hypertriglyceridemia with triglyceride levels <200 mg/dl at follow-up, which included a reduction in the incidence rates of pancreatitis,
9 44 The American Journal of Medicine, Vol 127, No 1, January 2014 overall cardiovascular events, acute myocardial infarction, ischemic stroke, heart failure, revascularization, and acute coronary syndrome. ACKNOWLEDGMENTS The authors thank Paul Buzinec, MS, Randall Gerdes, and Jonathan Kurlander, MS, who provided programming and analytic support, and Virginia M. Rosen, PhD, and Dawn Nicewarner, PhD, who provided editorial assistance on behalf of OptumInsight, which was contracted by Glaxo- SmithKline to conduct this study. References 1. Christian JB, Bourgeois N, Snipes R, Lowe KA. Prevalence of severe (500 to 2,000 mg/dl) hypertriglyceridemia in United States adults. Am J Cardiol. 2011;107: Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81(4A):7B-12B. 3. Gan SI, Edwards AL, Symonds CJ, Beck PL. Hypertriglyceridemiainduced pancreatitis: a case-based review. World J Gastroenterol. 2006;12: Greenberg BH, Blackwelder WC, Levy RI. Primary type V hyperlipoproteinemia. A descriptive study in 32 families. Ann Intern Med. 1977;87: Steiner G, Adelman AG, Silver MD. Early coronary atherosclerosis in primary type V hyperlipoproteinemia. Can Med Assoc J. 1971;105: Neil HA, Cooper J, Betteridge DJ, et al. All-cause and cardiovascular mortality in treated patients with severe hypertriglyceridaemia: a longterm prospective registry study. Atherosclerosis. 2010;211: National Cholesterol Education Program. Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): Final Report Available at: guidelines/cholesterol/index.htm. Accessed October 23, Lloret Linares C, Pelletier AL, Czernichow S, et al. Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas. 2008;37: Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123: Christian JB, Arondekar B, Buysman EK, Johnson SL, Seeger JD, Jacobson TA. Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dl in patients with severe hypertriglyceridemia. J Clin Lipidol. 2012;6: Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31: Brunzell JD. Clinical practice. Hypertriglyceridemia. N Engl J Med. 2007;357: Health Insurance Portability and Accountability Act of Public law , 104th Congress. 2011/09/23/ Available at: Accessed October 23, Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. MedCare. 2005;43: Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3: Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302: Tirosh A, Rudich A, Shochat T, et al. Changes in triglyceride levels and risk for coronary heart disease in young men. Ann Intern Med. 2007;147: Miller M. Dyslipidemia and cardiovascular risk: the importance of early prevention. QJM. 2009;102: Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298: Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:
10 Christian et al Triglyceride Levels and Clinical Impact 44.e1 Appendix Table 1 Diagnosis Codes for Clinical Outcomes Condition ICD-9 Diagnosis ICD-9 Procedure CPT Pancreatitis 577.0, Cardiovascular events Acute myocardial infarction 410.xx Ischemic stroke , , , , , , , , Hemorrhagic stroke 430, 431, 432.x Heart failure , , , , , , , , , 428.xx Revascularization (percutaneous coronary interventions including, percutaneous transluminal coronary angioplasty, and 00.66, 36.1x, , , , S2205-S2209, , , G0290-G0291, coronary artery bypass graft) Acute coronary syndrome 411.xx Sudden death 427.5, 798.x CPT ¼ Current Procedural Terminology; ICD-9 ¼ International Classification of Diseases, 9th Revision. Appendix Table 2 Summary of the Covariates Included in Each Model Adjusted Cox Proportional Hazards Models Pancreatitis* Cardiovascular Event Baseline covariates Follow-up triglyceride level group x x Age category (18-44 y, y, >65 y) x x Gender x x Quan-Charlson comorbidity score x x Region (Northeast, Midwest, South, and West) x x High-density lipoprotein C x Nonehigh-density lipoprotein C x x Index triglycerides laboratory value x x Baseline diagnoses Pancreatitis x x Cardiovascular disease x Hypertension x Chronic kidney disease/end-stage renal disease x x Diabetes diagnosis x x Baseline medication use Statins x x Triglyceride-lowering drug x x Beta-blocker x Hormone replacement therapy x *Hormone replacement therapy and steroid use did not alter the adjusted estimate and therefore were not included in the pancreatitis final model. Includes acute myocardial infarction, ischemic stroke, hemorrhagic stroke, sudden death, acute coronary syndrome, revascularization, and heart failure events. Includes the use of omega-3-acid ethyl esters (Lovaza; GlaxoSmithKline, Brentford, UK), nicotinic acid, or fibric acid.
Clinical Study HDL-C Response Variability to Niacin ER in US Adults
Cholesterol, Article ID 68147, 8 pages http://dx.doi.org/.11/13/68147 Clinical Study Response Variability to Niacin ER in US Adults Jennifer B. Christian, 1 Eric J. Olson, 2 Jeffery K. Allen, 3 and Kimberly
More informationAttendance rates and outcomes of cardiac rehabilitation in Victoria, 1998
Attendance rates and outcomes of cardiac rehabilitation in Victoria, 1998 CARDIOVASCULAR DISEASE is the leading cause of death in Australia, causing more than 40% of all deaths in 1998. 1 Cardiac rehabilitation
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationSupplementary Online Content
Supplementary Online Content Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. Published online November 7, 2016.
More informationHae Sun Suh, B.Pharm., Ph.D. Jason N. Doctor, Ph.D.
Podium Presentation, May 18, 2009 Comparison of Cardiovascular Event Rates in Subjects with Type II Diabetes Mellitus who Augmented from Statin Monotherapy to Statin Plus Fibrate Combination Therapy with
More informationThe University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
More informationSupplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
More informationNormal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis
CLINICAL RESEARCH STUDY Normal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis Gregory A. Nichols, PhD, Teresa A. Hillier, MD, MS, Jonathan B. Brown, PhD, MPP Center for Health Research, Kaiser
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationZhao Y Y et al. Ann Intern Med 2012;156:
Zhao Y Y et al. Ann Intern Med 2012;156:560-569 Introduction Fibrates are commonly prescribed to treat dyslipidemia An increase in serum creatinine level after use has been observed in randomized, placebocontrolled
More informationApolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease. Original Policy Date
MP 2.04.13 Apolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with
More information10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice
10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice Ajar Kochar, MD on behalf of: Anita Y. Chen, Puza P. Sharma, Neha J. Pagidipati, Gregg C. Fonarow, Patricia
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationSUPPLEMENTARY DATA. Table of Contents
Table of Contents Supplemental Figure S1. Kaiser Permanente Diabetes Registry Patient Flow Diagram Supplemental Table S1. Diagnostic and procedure codes and frequency of events during follow-up for outcomes
More informationTable 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use
Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)
More informationISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW
ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP: #204. Ischemic Vascular Disease (IVD):
More informationJacqueline C. Barrientos, Nicole Meyer, Xue Song, Kanti R. Rai ASH Annual Meeting Abstracts 2015:3301
Characterization of atrial fibrillation and bleeding risk factors in patients with CLL: A population-based retrospective cohort study of administrative medical claims data in the U.S. Jacqueline C. Barrientos,
More informationJournal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL
More informationMisperceptions still exist that cardiovascular disease is not a real problem for women.
Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees
More informationNon-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus
Diabetologia (2011) 54:73 77 DOI 10.1007/s00125-010-1945-z SHORT COMMUNICATION Non-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus S. van Dieren & U. Nöthlings & Y.
More informationApproximately 34% of adults in the United States
RESEARCH Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationRe-assessing the role of non-fasting lipids; a change in perspective
Editorial Page 1 of 5 Re-assessing the role of non-fasting lipids; a change in perspective Zareen Farukhi 1,2, Samia Mora 1,2 1 Center for Lipid Metabolomics, Division of Preventive Medicine, 2 Department
More informationCLINICAL. Determinants of Compliance With Statin Therapy and Low-Density Lipoprotein Cholesterol Goal Attainment in a Managed Care Population
Determinants of Compliance With Statin Therapy and Low-Density Lipoprotein Cholesterol Goal Attainment in a Managed Care Population Jennifer S. Schultz, PhD; John C. O Donnell, PhD; Ken L. McDonough, MD;
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More informationSection Editor Mason W Freeman, MD
Official reprint from UpToDate www.uptodate.com 2015 UpToDate The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club Announcements Next journal club Thursday, Dec. 14 th at 3:00 PM EST PACIFY Trial Effects of IV Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients
More informationDescription of Discordance Between LDL Cholesterol, Non-HDL Cholesterol, and LDL Particle Number Among Patients of a Lipid Clinic
Volume 8 Number 3 Article 14 9-26-2017 Description of Discordance Between LDL Cholesterol, Non-HDL Cholesterol, and LDL Particle Number Among Patients of a Lipid Clinic Joshua W. Gaborcik The Ohio State
More informationClinical Practice Guideline
Clinical Practice Guideline Secondary Prevention for Patients with Coronary and Other Vascular Disease Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC)
More informationIntercommunale de Santé Publique du Pays de Charleroi, Charleroi, Belgium 2
Lipid Abnormalities Remain High among Treated Hypertensive Patients with Stable CHD: Results of the Dyslipidemia International Study (DYSIS) II Belgium Michel Guillaume 1, Eric Weber 2, Johan De Sutter
More informationNonfasting LDL-C as a Predictor of Cardiovascular Event Risk
Pacific University CommonKnowledge School of Physician Assistant Studies Theses, Dissertations and Capstone Projects Summer 8-13-2016 Nonfasting LDL-C as a Predictor of Cardiovascular Event Risk Richard
More informationExercise treadmill testing is frequently used in clinical practice to
Preventive Cardiology FEATURE Case Report 55 Commentary 59 Exercise capacity on treadmill predicts future cardiac events Pamela N. Peterson, MD, MSPH 1-3 David J. Magid, MD, MPH 3 P. Michael Ho, MD, PhD
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationJae Jin An, Ph.D. Michael B. Nichol, Ph.D.
IMPACT OF MULTIPLE MEDICATION COMPLIANCE ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE II DIABETES AND COMORBID HYPERTENSION CONTROLLING FOR ENDOGENEITY BIAS Jae Jin An, Ph.D. Michael B. Nichol, Ph.D.
More informationCancer treatment has evolved considerably in the
Service Setting Impact on Costs for Bevacizumab-Treated Oncology Patients Nicole M. Engel-Nitz, PhD; Elaine B. Yu, PharmD, MS; Laura K. Becker, MS; and Art Small, MD Cancer treatment has evolved considerably
More informationPREDIABETES TESTING SERVICES
PREDIABETES TESTING SERVICES ASSESSING DIABETES RISK IN ASYMPTOMATIC ADULTS Depending upon population characteristics, up to 70% of individuals with prediabetes will ultimately progress to diabetes at
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationA Systematic Approach to Improve Lipids in Coronary Artery Disease Patients Participating in a Cardiac Rehabilitation Program
c e... A Systematic Approach to Improve Lipids in Coronary Artery Disease Patients Participating in a Cardiac Rehabilitation Program Sophia Boudoulas Meis, DO; Richard Snow, DO; Michelle LaLonde, MS; James
More informationMeasure Owner Designation. AMA-PCPI is the measure owner. NCQA is the measure owner. QIP/CMS is the measure owner. AMA-NCQA is the measure owner
2011 EHR Measure Specifications The specifications listed in this document have been updated to reflect clinical practice guidelines and applicable health informatics standards that are the most current
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Statin Therapy Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Statin Therapy Prime Therapeutics will review Prior Authorization requests. Prior Authorization
More informationMetabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD
Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy
More informationCost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T
Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T Record Status This is a critical abstract of an economic evaluation
More informationUnderstanding Cholesterol and Triglycerides
MINTO PREVENTION & REHABILITATION CENTRE CENTRE DE PREVENTION ET DE READAPTATION MINTO Understanding Cholesterol and Triglycerides About This Kit Along with cigarette smoking, high blood pressure, physical
More informationAHA Clinical Science Special Report: November 10, 2015
www.canheart.ca High-density lipoprotein cholesterol and cause-specific mortality: A population-based study of more than 630,000 individuals without prior cardiovascular conditions Dennis T. Ko, MD, MSc;
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More informationLDL How Low can (should) you Go and be Safe
LDL How Low can (should) you Go and be Safe Edward Shahady MD, FAAFP, ABCL Clinical Professor Family Medicine Medical Director Diabetes Master Clinician Program Definition of Low LDL National Health and
More informationData Fusion: Integrating patientreported survey data and EHR data for health outcomes research
Data Fusion: Integrating patientreported survey data and EHR data for health outcomes research Lulu K. Lee, PhD Director, Health Outcomes Research Our Development Journey Research Goals Data Sources and
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life
More informationNon-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017
Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017 Historical Basis for Fasting Lipids The initial classifications of hyperlipidemia proposed in 1967 were genetic and required
More informationZuhier Awan, MD, PhD, FRCPC
Metabolism, Atherogenic Properties and Agents to Reduce Triglyceride-Rich Lipoproteins (TRL) The Fifth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 8-11, 2019 Zuhier
More informationSupplementary Online Content
Supplementary Online Content Dharmarajan K, Wang Y, Lin Z, et al. Association of changing hospital readmission rates with mortality rates after hospital discharge. JAMA. doi:10.1001/jama.2017.8444 etable
More informationThe Cost Effectiveness of Omacor post-myocardial infarction in the Irish Healthcare Setting
The Cost Effectiveness of Omacor post-myocardial infarction in the Irish Healthcare Setting April 2013 1. Omacor is a concentrated preparation of omega-3-acid ethyl esters that contains 46% eicosapentaenoic
More informationHDL-C. J Jpn Coll Angiol, 2008, 48: NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart
Online publication March 25, 2009 48 6 2007 2007 HDL-C LDL-C HDL-C J Jpn Coll Angiol, 2008, 48: 463 470 NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart 1987 NIPPON DATA80 Iso 10 MRFIT
More informationAchieving Cholesterol Management Goals: Identifying Clinician-Centered Challenges to Optimal Patient Care
Achieving Cholesterol Management Goals: Identifying Clinician-Centered Challenges to Optimal Patient Care Purpose Explore the adherence rates to cholesterol treatment targets among patients who seek care
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationGSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDyslipidemia in women: Who should be treated and how?
Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More informationCLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016
CLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016 WHAT IS AN EPISODE OF CARE? An episode of care is a grouping of a patient s health care claims for a unique
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More informationEstablished Risk Factors for Coronary Heart Disease (CHD)
Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland
More informationResearch Article Discordance of Non-HDL and Directly Measured LDL Cholesterol: Which Lipid Measure is Preferred When Calculated LDL Is Inaccurate?
Hindawi Publishing Corporation Cholesterol Volume 13, Article ID 52948, 6 pages http://dx.doi.org/.1155/13/52948 Research Article Discordance of Non-HDL and Directly Measured LDL Cholesterol: Which Lipid
More informationLipoprotein Subclassification Testing for Screening, Evaluation and Monitoring of Cardiovascular Disease
for Screening, Evaluation and Monitoring of Cardiovascular Disease Last Review Date: June 9, 2017 Number: MG.MM.LA.40Cv2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACC/AHA. See American College of Cardiology/ ACE inhibitors. See Angiotensin-converting enzyme (ACE) inhibitors American College of Cardiology/American
More informationLIPIDS AND CHOLESTEROL - RISK FACTORS TO A POLICE UNIT FROM BRASOV
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 4 (53) No. 2-2011 LIPIDS AND CHOLESTEROL - RISK FACTORS TO A POLICE UNIT FROM BRASOV C. DOBRESCU 1 I. MOLEAVIN 1 Abstract:
More informationDisclosures. Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA. Learning Objectives. Atherogenesis. Acceptable Values
39 th National Conference on Pediatric Health Care Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA March 19-22, 2018 CHICAGO Disclosures Speakers Bureau Sanofi and Regeneron Learning Objectives
More informationCARING FOR A LOVED ONE AFTER A HEART ATTACK OR STROKE
CARING FOR A LOVED ONE AFTER A HEART ATTACK OR STROKE AFTER YOUR LOVED ONE HAS HAD A HEART ATTACK OR STROKE Heart attack and stroke affects the whole family. If your loved one has had a heart attack or
More informationProgram Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.
More informationSummary of Research and Writing Activities In Cardiovascular Disease
Summary of Research and Writing Activities In Cardiovascular Disease Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts
More informationPAD Characterization Within A Healthcare System" RAPID Face-to-Face Meeting Schuyler Jones, MD September 14, 2016
PAD Characterization Within A Healthcare System" RAPID Face-to-Face Meeting Schuyler, MD September 14, 2016 Interventional Cardiology and Cath Labs Disclosures Research Grants: Agency for Healthcare Research
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationChapter 4: Cardiovascular Disease in Patients With CKD
Chapter 4: Cardiovascular Disease in Patients With CKD The prevalence of cardiovascular disease is 68.8% among patients aged 66 and older who have CKD, compared to 34.1% among those who do not have CKD
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationChapter 4: Cardiovascular Disease in Patients with CKD
Chapter 4: Cardiovascular Disease in Patients with CKD The prevalence of cardiovascular disease (CVD) was 65.8% among patients aged 66 and older who had chronic kidney disease (CKD), compared to 31.9%
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationARE YOU AT RISK OF A HEART ATTACK OR STROKE? Understand How Controlling Your Cholesterol Reduces Your Risk
ARE YOU AT RISK OF A HEART ATTACK OR STROKE? Understand How Controlling Your Cholesterol Reduces Your Risk CONSIDER YOUR HEART HEALTH: REDUCE YOUR CHOLESTEROL Uncontrolled or continuous high cholesterol
More informationCardiovascular Controversies: Emerging Therapies for Lowering Cardiovascular Risk
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More information2013 Hypertension Measure Group Patient Visit Form
Please complete the form below for 20 or more unique patients meeting patient sample criteria for the measure group for the current reporting year. A majority (11 or more) patients must be Medicare Part
More informationMedical evidence suggests that
COMBINATION THERAPY TO ACHIEVE LIPID GOALS David G. Robertson, MD* ABSTRACT Coronary heart disease (CHD) remains the leading cause of death in the United States despite recent advances in treatment and
More informationThe apolipoprotein story
Atherosclerosis Supplements 7 (2006) 23 27 The apolipoprotein story Frank M. Sacks a,b, a Department of Nutrition, Harvard School of Public Health, Boston, MA, USA b Department of Medicine, Harvard Medical
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationFinland and Sweden and UK GP-HOSP datasets
Web appendix: Supplementary material Table 1 Specific diagnosis codes used to identify bladder cancer cases in each dataset Finland and Sweden and UK GP-HOSP datasets Netherlands hospital and cancer registry
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationClinical and Economic Summary Report. for Employers
Clinical and Economic Summary Report for Employers Magaly Rodriguez de Bittner, PharmD, CDE, FAPhA Director, P 3 Program Dawn Shojai, PharmD Assistant Director, P 3 Program P 3 Clinical & Economic Summary
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationClinical Therapeutics/Volume 33, Number 1, 2011
Clinical Therapeutics/Volume 33, Number 1, 2011 Concurrent Control of Blood Glucose, Body Mass, and Blood Pressure in Patients With Type 2 Diabetes: An Analysis of Data From Electronic Medical Records
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More information